(Q34438400)

2 August 2017

The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women (English)

1 reference

2 August 2017

Donna Kritz-Silverstein

4

object named as

Kritz-Silverstein D

1 reference

2 August 2017

Elizabeth Barrett-Connor

1

object named as

Barrett-Connor E

1 reference

2 August 2017

Slone S

2

1 reference

2 August 2017

Greendale G

3

1 reference

2 August 2017

Espeland M

5

1 reference

2 August 2017

Johnson SR

6

1 reference

2 August 2017

Waclawiw M

7

1 reference

2 August 2017

Fineberg SE

8

1 reference

2 August 2017

1 July 1997

1 reference

2 August 2017

1 reference

2 August 2017

27

1 reference

2 August 2017

261-274

1 reference

2 August 2017

3

1 reference

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Rationale, design, and conduct of the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Recruitment of postmenopausal women in the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Enzymatic methods for quantification of lipoprotein lipids

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Precipitation methods for quantification of lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Determination of Glucose in Blood Using Glucose Oxidase with an Alternative Oxygen Acceptor

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

[Rapid physiological coagulation method in determination of fibrinogen]

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

High density lipoprotein cholesterol and incidence of coronary heart disease--the Israeli Ischemic Heart Disease Study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Plasma lipoprotein levels as predictors of cardiovascular death in women.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Ovarian sex steroids and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Oestrogens and atherosclerotic vascular disease--local vascular factors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Time to stop counting the tablets?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

The run-in period in clinical trials. The effect of misclassification on efficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Controversy in Counting and Attributing Events in Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Controversies and achievements in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

Hormone therapy to prevent disease and prolong life in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2897%2900041-8

7 January 2021

10.1016/S0378-5122(97)00041-8

Identifiers

DOI

1 reference

2 August 2017

1 reference